Literature DB >> 17539994

Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report.

Yuichi Torisu1, Kenji Ikeda, Masahiro Kobayashi, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Yusuke Kawamura, Hiromi Yatsuji, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada.   

Abstract

AIM: Diabetes mellitus (DM) has been reported to increase the risk of hepatocellular carcinogenesis in chronic liver diseases. This study aims to elucidate whether DM is an independent risk factor for the appearance of hepatocellular carcinoma (HCC) in patients with alcoholic cirrhosis.
METHODS: Forty-seven patients with alcoholic cirrhosis were retrospectively observed for a median of 6.8 years. The patients showed a history of heavy alcohol intake of 500 kg or more until the diagnosis of cirrhosis, and no patients had hepatitis B surface antigen, hepatitis B virus DNA measured by nested polymerase chain reaction, or antihepatitis C virus.
RESULTS: During the observation period, HCC developed in nine patients (19.1%). Cumulative appearance rates of HCC were 10.5%, 23.8% and 33.3% at the end of the fifth, 10th and 15th years, respectively. When they were divided into two groups according to the association of diabetes, carcinogenesis rates in patients with (n = 11) and without (n = 36) DM, cumulative carcinogenesis rates were 32.7% and 3.2% at the end of fifth year, 32.7% and 20.2% at the tenth year, and 66.3% and 20.2% at the 15th year, respectively. Crude carcinogenesis rate in the patient with DM was significantly higher than that of patients without DM (P = 0.0034). Multivariate analysis disclosed a higher age (hazard ratio 28.1, P = 0.007), and association of DM (hazard ratio 21.7, P = 0.006) significantly affected future carcinogenesis rate.
CONCLUSION: DM seemed to be an independent risk factor for hepatocarcinogenesis in the cohort study of patients with alcoholic cirrhosis.

Entities:  

Year:  2007        PMID: 17539994     DOI: 10.1111/j.1872-034X.2007.00077.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  14 in total

1.  Postoperative outcomes of patients with hepatocellular carcinoma negative for all virus-related markers.

Authors:  Ichiro Yamato; Tadatoshi Takayama; Yutaka Midorikawa; Tokio Higaki; Hisashi Nakayama; Masamichi Moriguchi; Yoshiyuki Nakajima; Shunichi Matsuoka; Masahiro Ogawa; Mitsuhiko Moriyama
Journal:  Surg Today       Date:  2012-08-28       Impact factor: 2.549

2.  Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1.

Authors:  Teruko Hino-Arinaga; Tatsuya Ide; Ryoko Kuromatsu; Ichiro Miyajima; Kei Ogata; Reiichiro Kuwahara; Akiko Hisamochi; Takuji Torimura; Michio Sata
Journal:  J Gastroenterol       Date:  2011-12-21       Impact factor: 7.527

3.  Selection criteria for hepatectomy in patients with hepatocellular carcinoma classified as Child-Pugh class B.

Authors:  Shintaro Kuroda; Hirotaka Tashiro; Tsuyoshi Kobayashi; Akihiko Oshita; Hironobu Amano; Hideki Ohdan
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

4.  Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.

Authors:  Manal M Hassan; Steven A Curley; Donghui Li; Ahmed Kaseb; Marta Davila; Eddie K Abdalla; Milind Javle; Dalia M Moghazy; Richard D Lozano; James L Abbruzzese; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

Review 5.  Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.

Authors:  Tracey G Simon; Andrew T Chan
Journal:  Clin Liver Dis       Date:  2020-08-25       Impact factor: 6.126

Review 6.  The impact of obesity and metabolic syndrome on alcoholic liver disease.

Authors:  Dian J Chiang; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2013-10-24       Impact factor: 6.126

7.  The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.

Authors:  Wan-Shui Yang; Puthiery Va; Freddie Bray; Shan Gao; Jing Gao; Hong-Lan Li; Yong-Bing Xiang
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

8.  Cancer risk in HBV patients with statin and metformin use: a population-based cohort study.

Authors:  Chang-I Chen; Ching-Feng Kuan; Yu-Ann Fang; Shing-Hwa Liu; Ju-Chi Liu; Li-Li Wu; Chun-Jen Chang; Hsuan-Chia Yang; Jaulang Hwang; James S Miser; Szu-Yuan Wu
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

9.  Type 2 diabetes mellitus increases liver transplant-free mortality in patients with cirrhosis: A systematic review and meta-analysis.

Authors:  Zi-Jin Liu; Yi-Jie Yan; Hong-Lei Weng; Hui-Guo Ding
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

10.  S-Allyl cysteine improves nonalcoholic fatty liver disease in type 2 diabetes Otsuka Long-Evans Tokushima Fatty rats via regulation of hepatic lipogenesis and glucose metabolism.

Authors:  Shigekazu Takemura; Yukiko Minamiyama; Shintaro Kodai; Hiroji Shinkawa; Takuma Tsukioka; Shigeru Okada; Hideki Azuma; Shoji Kubo
Journal:  J Clin Biochem Nutr       Date:  2013-08-31       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.